Table 1. Clinical characteristics of 281 patients with breast cancer.
| Characteristics | Mean (range) or n (%) |
|---|---|
| Age (years) | 45.4 (27.3-73.7) |
| Body mass index (kg/m2) | 22.9 (16.8-36.4) |
| Menopausal status, n (%) | |
| Pre/peri-menopause | 208 (74.0) |
| Post-menopause | 73 (26.0) |
| Tamoxifen duration at initial blood collection time (days) | 125 (56-340) |
| Dose of tamoxifen (mg/day) | 20 |
| Neoadjuvant chemotherapy | |
| No | 274 (97.5) |
| Yes | 7 (2.5) |
| Adjuvant chemotherapy | |
| No | 148 (52.7) |
| Yes | 133 (47.3) |
| Stage | |
| 0 | 61 (21.7) |
| 1 | 118 (42.0) |
| 2 | 74 (26.3) |
| 3 | 28 (10.0) |
| Nuclear grade | |
| 1 | 78 (27.8) |
| 2 | 132 (47.0) |
| 3 | 68 (24.2) |
| Unknown | 3 (1.1) |
| Number of measurement, n (%) | |
| Once | 102 (36.3) |
| Twice | 89 (31.7) |
| Thrice | 90 (32.0) |
| Concomitant medicine, n (%)a | |
| Goserelin | 43 (7.8) |
| Levothyroxin | 11 (2.0) |
| Calcium carbonate/cholecalciferol | 7 (1.3) |
| Valsaltan | 6 (1.1) |
| Amlodipine | 5 (0.9) |
| CYP inhibitorb | 3 (0.5) |
| Othersc | 25 (4.5) |
| Not used | 473 (86.0) |
aDenominator is the total number of blood collection time (550).
bEscitalopram, hydroxyzine, and ranitidine.
cAceclofenac, atorvastatin, alendronate, calcium polycarbophil, cefdinir, cefditoren, gabapentin, gliclazide, herceptin, hydrochlorothiazide, insulin, itopride, lamotrigine, losartan/hydrochlothiazide, magnesium oxide, metformin, pethidine, ramipril, risedronate, rosuvastatin, sitagliptin, tizanidine, tobramycin, tramadol, triazolam, valaciclovir, venlafaxine, voglibose, zaltoprofen, zoledronic acid, and zolpidem.